

SCIENTIFIC REPORTS



OPEN

Antibodies against a β -glucan-protein complex of *Candida albicans* and its potential as indicator of protective immunity in candidemic patients

Antonella Torosantucci¹, Mario Tumbarello², Carla Bromuro¹, Paola Chiani¹, Brunella Posteraro³, Maurizio Sanguinetti⁴, Roberto Cauda² & Antonio Cassone⁵

Sera from candidemic and non-candidemic subjects were examined for antibodies against the cell wall β 1,3- and β 1,6-glucans, as well as the β -glucan-associated protein MP65 of *Candida* species. Although antibodies against each of the above components were detected in all subjects, candidemic patients had lower antibody titers against β 1,3-glucan, but higher antibody titers against β 1,6-glucan and MP65, than non-candidemic subjects. The elevated levels of anti- β 1,6-glucan and -MP65 antibodies found in candidemic patients were independent on the patient risk category, APACHE II score, presence of co-morbidities, β 1,3-glucanemia level, *Candida* isolate, and antifungal treatment. Interestingly, however, the anti-MP65, but not the anti- β 1,6-glucan antibodies, of candidemic patients had higher titers in survivors than in non-survivors, particularly in those subject categories with the highest mortality (>65-years old, diabetic, or septic shock patients). Thus, candidemic patients are capable of boosting anti-*Candida* immune responses upon infection, and some of these responses might be associated to the generation of protective immunity in patients with candidemia.

Candidemia is a remarkable health threat to hospitalized patients, including non-neutropenic subjects with advanced age and co-morbidities^{1–3}. Despite progress in epidemiology, diagnosis and therapy, candidemia remains associated with high mortality (30–50%) and increasing incidence^{1, 3–7}. In some hospital settings, *Candida* spp. are among the most frequent causes of bloodstream infections^{1, 8, 9}.

While many risk factors which make a subject prone to develop the disease are known, and include deep surgery and a number of invasive, medical-associated technologies, those influencing disease outcome are only partially known and remain somewhat debated¹⁰. Data on causative *Candida* spp. and their antifungal resistance are widely available and suggest influence of local epidemiology on infection and possibly also on its outcome^{8, 11–14}. A role for older age, inappropriate or non-timely antifungal therapy and general patient conditions on mortality rate appears to be plausible, though marked differences among the different studies have been reported^{5, 8, 13–16}.

Only few studies have directly addressed the presence and magnitude of anti-*Candida* immunity, in particular antibody responses, in the above patients, mostly with the aim of providing diagnostic indicators^{17–24}. We are studying antibody responses in candidemia with the main purpose of assessing whether and to what extent antibodies to key structural and/or functional fungal antigens could be used as prognostic indicators and as a guide to identify new vaccine candidates. Following this research line, we have now focused on antibodies against a major polysaccharide-protein complex that is commonly present in *Candida* species causing candidemia. This complex contains both β 1,3- and β 1,6 glucans, of which the former is a currently accepted diagnostic marker of

¹Department of Infectious, Parasitic and Immune-mediated Diseases, Istituto Superiore di Sanità, 00161, Rome, Italy. ²Institute of Infectious Diseases, Catholic University of the Sacred Heart, 00168, Rome, Italy. ³Institute of Public Health, Catholic University of the Sacred Heart, 00168, Rome, Italy. ⁴Institute of Microbiology, Catholic University of the Sacred Heart, 00168, Rome, Italy. ⁵Polo d'innovazione della genomica, genetica e biologia, University of Perugia, 71000, Perugia, Italy. Correspondence and requests for materials should be addressed to A.C. (email: a.cassone@pologgb.com)

candidemia and a molecular pattern recognized by a major receptor, Dectin-1, commonly expressed on cells of innate immunity^{25, 26}. The complex also contains a β -glucan-associated mannoprotein, MP65, with a putative endo-glucanase activity which plays a critical role for cell wall growth and stability, and is a major target of anti-*Candida* adaptive immunity in humans^{27, 28}.

Here we report that candidemic subjects are able to boost the anti-*Candida* response normally associated with colonization, and suggest that the capacity of boosting some of the above responses could indicate the generation of protective immunity, hence impact on disease outcome.

Results

Clinical and laboratory data. Seventy one candidemic patients (40 males and 31 females; mean age 67.2 ± 3.1 ; median 72.0) and sixty nine age- and sex-matched control patients entered this study. All candidemic patients had *Candida*-positive blood cultures, positive β -glucanemia and signs and symptoms of the infection. For candidemic patients, the median duration of hospitalization and the APACHE II score at the time of the first positive blood culture were 21.5 days (range 2–180) and 16 (range 5–37), respectively. Thirty four subjects had a central venous catheter inserted. About half of the patients underwent previous surgery and for only seven of them there was evidence for immunosuppression. The vast majority of patients were treated with anidulafungin or caspofungin.

The controls were patients who were admitted to the hospital within the same period of time as the candidemic ones and were considered at risk for candidemia, but with *Candida*-negative blood-culture and negative β -glucanemia. Among them, 25 had a central venous catheter inserted, 30 had previous surgery, 6 were diabetics and 39 had previous antibiotic treatment. Other details are reported in the Supplementary Table 1.

Isolates from six *Candida* species were obtained from candidemic subjects, about 60% being *C. albicans*, alone or together with another species, followed by *C. parapsilosis* (19.7%), *C. glabrata* (7.0%), *C. tropicalis* (7.0%), and one isolate each of other minor *Candida* species. Of our patients, 31 (43.7%) did not survive. The mortality appeared to be associated with older age ($P = 0.03$), septic shock ($P = 0.008$), and diabetes mellitus ($P = 0.008$) but neither with APACHE II score, previous surgery, or other co-morbidities. The clinical data are detailed in Table 1.

Levels of serum anti- β -glucan or anti-MP65 IgG antibodies in candidemic patients. Presence and titers of anti- β -glucan and anti-MP65 antibodies at onset of candidemia were determined in sera from candidemic patients, taken at time of laboratory diagnosis of the first candidemia episode, and compared to those of non-candidemic controls. Both laminarin (β 1,3-glucan) and pustulan (β 1,6-glucan) were initially used as representative of *Candida* β -glucan antigens. However, most candidemic patients showed high levels (≥ 500 pg/ml; Table 1) of circulating β 1,3-glucan that could strongly bind the respective specific antibodies and make them poorly detectable in our ELISA test. In support of this interpretation, we found that our candidemic patients had significantly lower titers of anti- β 1,3-glucan (laminarin) antibodies, as compared to the control group (Fig. 1A), and that their levels of anti- β 1,3-glucan IgGs were inversely related to the amount of serum β 1,3-glucan (Fig. 1B). In contrast, there was no significant correlation between β 1,3-glucanemia and titers of anti- β 1,6-glucan (pustulan) IgGs (Fig. 1C). For this reason, only the anti- β 1,6-glucan IgGs were further examined in this study as representative of genuine titers of antibody against *Candida* β -glucan.

Figure 2 shows IgG titers against β 1,6-glucan and MP65 in candidemic patients in comparison with the same antibodies in controls. The candidemic patients had higher IgG titers than controls against both MP65 ($P < 0.0001$) and β 1,6-glucan ($P = 0.002$). The ROC curves generated from these assays (Supplemental Figure S1) showed that titers of anti-MP65 IgGs could better discriminate candidemic from non-candidemic patients (AUC = 0.78, sensitivity 76 or 62% and specificity 59 or 90% at a cutoff of > 1200 or > 2400 , respectively) than those of anti- β 1,6-glucan IgGs (AUC = 0.65, sensitivity 55 or 40% and specificity 52 or 40% at a cutoff of > 4800 or > 9600 , respectively).

The specificity of our anti-MP65 IgG ELISA was confirmed by qualitative western blot analyses of representative sera from candidemic and non-candidemic subjects using an anti-MP65 monoclonal antibody as positive control²⁷. These assays clearly showed that the binding pattern of human sera substantially overlapped the one exhibited by the MP65-specific monoclonal antibody, with a reaction intensity in good apparent correlation with the anti-MP65 ELISA titers (Supplemental Figure S2).

The difference in the levels of anti-MP65 serum antibodies between candidemic and non-candidemic patients was significant both in patients infected by *C. albicans* ($P < 0.0001$ vs controls) and in those infected by non-*albicans* *Candida* species ($P < 0.0001$ vs controls, Fig. 3). The anti-MP65 IgG titers were overall similar ($P > 0.05$) in candidemic patients receiving or not receiving supportive steroids and with or without septic shock. However, the titers of anti-MP65 IgGs in diabetic patients with candidemia had the lowest levels over those in control population (geometric mean 1,467, 95% CI 685–3141 vs 726, 541–975; $P = 0.37$) compared to the titers in non-diabetic, candidemic patients (geometric mean 3,160, 95% CI 2,239–4,269; $P < 0.0001$). There was no statistically significant correlation between β 1,3-glucanemia values and anti-MP65 IgG titers, nor there was correlation between antibody levels and patient age or APACHE II score (data not shown).

Relationship between levels of anti-MP65 IgGs and survival of candidemic patients. We examined whether there was any association between survival of patients with candidemia and titers of anti- β 1,6-glucan or anti-MP65 antibodies at candidemia diagnosis. As show in Fig. 4A, the survivors had overall higher antibody titers against both β 1,6-glucan and MP65 as compared to the non-survivors. In the case of MP65 antigen, the higher titers of survivors were statistically significant, a finding particularly notable in patients with the highest mortality in our setting, as those of older age, or diabetic or with septic shock (Fig. 4B). In fact, logistic regression analysis showed a significant, positive relationship between values (logarithm) of anti-MP65 titer and probability of survival, both in the whole population of candidemic patients (OR 2.61, CI 95% 1.01–6.75,

	All patients	Survivors	Non-survivors	P, survivors vs non-survivors	Odds ratio (95% confidence interval)
Candidemic patients, n (%)	71	40 (56.3)	31 (43.7)		
Sex					
Male, n/total (%)	40/71 (56.3)	22/40 (55.0)	18/40 (45.0)	0.81 ^a	0.88 (0.34–2.27)
Female, n/total (%)	31/71 (43.7)	18/31 (58.1)	13/31 (41.9)		
Age, median (range)	72 (14–91)	67.5 (20–86)	76 (14–91)	0.03^b	
Isolated <i>Candida</i> species, n/total (%)					
<i>C.albicans</i>	38/71 (53.5)	21/40 (52.5)	17/31 (54.8)		
<i>C.parapsilosis</i>	14/71 (19.7)	11/40 (27.5)	3/31 (9.7)		
<i>C.glabrata</i>	5/71 (7.0)	2/40 (5.0)	3/31 (9.7)		
<i>C.tropicalis</i>	5/71 (7.0)	2/40 (5.0)	3/31 (9.7)	1.0 ^c	0.91 (0.35–2.33)
<i>C.krusei</i>	1/71 (1.4)	1/40 (2.5)	0/31 (0)		
<i>C.guilliermondii</i>	1/71 (1.4)	0/40 (0)	1/31 (3.2)		
<i>C.lusitaniae</i>	1/71 (1.4)	1/40 (2.5)	0/31 (0)		
<i>C.robusta</i>	1/71 (1.4)	0/40 (0)	1/31 (3.2)		
<i>C.albicans</i> associated with other <i>Candida</i> species	5/71 (7.0)	2/40 (5.0)*	3/31 (9.7)**		
Antifungal treatment^d					
Anidulafungin	34/71 (47.9)	16/40 (40.0)	18/31 (58.0)		
Caspofungin	19/71 (26.8)	12/40 (30.0)	7/31 (22.6)	0.59 ^e	
Fluconazole	19/71 (26.8)	11/40 (27.5)	8/31 (25.8)		
Liposomal Amphotericin B	9/71 (12.7)	6/40 (15.0)	3/31 (9.7)		
Serum beta-glucan at the time of the first positive blood culture, median pg/ml (range)	>500 (97->500)	>500 (97->500)	>500 (135->500)	0.66 ^b	
Total duration of hospital stay at the time of the first positive blood culture, median days (range)	21.5 (2–180)	20 (2–71)	23 (3–180)	0.58 ^b	
Median (range) APACHE II score at the time of the first positive blood culture	16 (5–37)	15 (5–35)	16 (5–37)	0.26 ^b	
Septic shock, n/total (%)	37/71 (52.1)	15/40 (37.5)	22/31 (80.0)	0.008^a	4.07 (1.49–11.14)
Central venous catheter, n/total (%)	34/71 (47.8)	18/40 (45.0)	16/31 (51.6)	0.64 ^a	1.30 (0.50–3.33)
Previous surgery, n/total (%)	34/71 (47.8)	18/40 (45.0)	16/31 (51.6)	0.64 ^a	1.30 (0.50–3.33)
Hematomalignancy, n/total (%)	5/71 (7.0)	2/40 (5.0)	3/31 (9.7)	0.65 ^a	2.03 (0.32–13.01)
HIV, n/total (%)	1/71 (1.4)	0/40 (0)	1/31 (3.2)	na	na
Immunosuppressant, n/total (%)	7/71 (9.8)	5/40 (12.5)	2/31 (6.5)	0.46 ^a	0.48 (0.09–2.68)
Steroids, n/total (%)	20/71 (28.1)	13/40 (32.5)	7/31 (22.6)	0.43 ^a	0.61 (0.21–1.77)
Solid tumor, n/total (%)	16/71 (22.5)	8/40 (20.0)	8/31 (25.8)	0.58 ^a	1.39 (0.46–4.25)
Chronic obstructive pulmonary disease, n/total (%)	20/71 (28.2)	11/40 (27.5)	9/31 (29.0)	1.00 ^a	1.08 (0.38–3.05)
Chronic renal failure, n/total (%)	13/71 (18.3)	8/40 (20.0)	5/31 (16.1)	0.76 ^a	0.77 (0.22–2.64)
Diabetes mellitus, n/total (%)	16/71 (22.5)	4/40 (10.0)	12/31 (38.7)	0.008^a	5.68 (1.61–20.06)
Previous antibiotic treatment (30 days), n/total (%)	54/71 (76.1)	32/40 (80.0)	22/31 (70.9)	0.41 ^a	0.61 (0.20–1.83)

Table 1. Demographic, clinical and microbiological data of candidemic patients considered in the study.

^aFisher exact test; ^bMann-Whitney U test; ^{*}*C.albicans* + *C.krusei* (1), *C.albicans* + *C.guilliermondii* (1); ^{**}*C.albicans* + *C.glabrata* ^cFisher exact test evaluating isolation of *non-albicans* species, alone or in association, vs the isolation of *C.albicans* only ^dNine patients were treated with more than one antifungal ^eChi-square test na = not applicable.

$p = 0.047$) and in all three, high mortality-risk subpopulations (OR 17.7, CI95% 1.10–284.8, $p = 0.041$ in diabetic patients; OR 4.38, CI 95% 1.01–19.04, $p = 0.048$ in patients with septic shock; OR 3.78, CI 95% 1.07–13.29, $p = 0.038$ in patients of age >65 years). No significant association between survival and anti- β 1,6-glucan titers was instead found either in the whole population or in any category or sub-group of candidemic patients.

Discussion

In this study, we report novel observations about antibody responses against antigenic constituents of an immunodominant polysaccharide-protein complex of the cell wall of *Candida* spp. in candidemic and non-candidemic, control patients. The saccharide antigens are the β 1,3- and β 1,6-glucan polymers which are known to be involved in many critical aspects of host-parasite relationship in candidiasis^{29,30}. The protein antigen is MP65, a putative




Figure 1. Serum titers of anti- β 1,3-glucan IgG are lower in candidemic patients than in controls, and are inversely correlated to levels of circulating β 1,3-glucan. Panel a: Individual, anti- β 1,3-glucan IgG titers in patients with candidemia ($n = 71$) and in non-candidemic controls ($n = 69$). A single serum samples was analyzed for each subject. For candidemic patients, sera were those obtained at onset of candidemia, i.e. from the same blood specimen of the first *Candida*-positive blood culture. Geometric means are indicated by the lines. P was estimated by the Mann-Whitney U test. Panels b and c: Correlation between serum titers of anti- β 1,3-glucan (b) or anti- β 1,6-glucan (c) IgG and beta-glucanemia in candidemic patients. Correlation coefficients r_s and P values were calculated by the Spearman's rank correlation analysis.




Figure 2. Onset of candidemia is associated to a significant rise of anti-MP65 and anti- β 1,6-glucan antibodies. The graph shows the individual titers of anti-MP65 (Panel a) or anti- β 1,6-glucan IgGs (Panel b) measured in control ($n = 69$) and candidemic patients ($n = 71$). Sera of candidemic subjects (one for patient) were from the same blood specimen of the first *Candida*-positive blood culture. Lines are at geometrical mean titers. P values were calculated by the Mann-Whitney U test.




Figure 3. Levels of anti-MP65 IgGs are comparably increased in patients infected by *C. albicans* or by other, non-*albicans*, *Candida* species. The plot compares the distribution of anti-MP65 IgG titers in patients with *C. albicans* candidemia (n = 43), patients infected by other *Candida* species (n = 28) and non-candidemic controls (n = 69). Bottom and top of the box represent the first and third quartiles, respectively. Line inside the box is the median titer and whisker show minimum and maximum values. P was calculated by Kruskal-Wallis ANOVA and Dunn's post-test.




Figure 4. Comparison of anti-MP65 and anti- β 1,6-glucan antibody levels at candidemia diagnosis in survivors and non-survivors among candidemic patients. Panel a: Distribution of individual IgG titers against MP65 or β 1,6 glucan in survivors (n = 40) and non-survivors (n = 31). Panel b: Levels of anti-MP65 IgGs in surviving and non-surviving candidemic patients belonging to categories of high mortality risk in our setting (patients aged >65 years, with septic shock or with diabetes mellitus, n survivors vs n non-survivors = 22 vs 25, 15 vs 22 and 4 vs 12, respectively) Logistic regression analysis was used to calculate the Odds ratio for the relationship between survival and anti-MP65 and anti- β 1,6-glucan antibody titers.

endo-glucanase enzyme, usually found associated to β 1,3-glucan, and previously identified as a major target of T cell responses to *C. albicans*^{27,28}. Both β -glucans and MP65 have been shown to be expressed and abundantly secreted by yeast and hyphal cells of *C. albicans* in which they play an essential physiological role for cell wall growth and pathogenesis, including adherence to host cells and biofilm formation^{28,30}. Less is known regarding these antigens in other pathogenic *Candida* spp., where, however, they are present³¹ and possibly play similar roles as in *C. albicans*. Because of their strong involvement in the fungal biology and immune response, we considered of special relevance to assess the antibody response to these constituents in candidemic subjects. In fact, few studies have addressed antibody responses in candidemic subjects, mostly for diagnostic purposes^{17–24}, and none of them specifically investigated the antibodies to the β -glucan complex of *Candida* cell wall. A report by Pitarch and coworkers describing a *C. albicans* immune serological proteome²³ showed that candidemic subjects have serum antibodies against a high number of fungus proteins and their peptide sequences, most of which were poorly or not represented at all in non-candidemic subjects. Other authors have recently reported on the presence in candidemic subjects of dominant antibodies against proteins secreted during yeast to hypha transition of *C. albicans* and highlighted the importance of the glycosylated moieties of these proteins as target of antibody responses¹⁹. Overall, non-immunocompromised candidemic patients are evidently able to raise anti-*Candida*

responses during the infection, some of which have also been assumed to be of diagnostic relevance^{21, 22, 24, 25}. Here we report that candidemic patients, at the time of candidemia diagnosis, had significantly higher titers of anti-MP65 and anti- β 1,6-glucan antibodies than non-candidemic subjects. The higher anti-MP65 titers of candidemic patients were not restricted to those infected by *C. albicans*, corroborating the notion that this important antigen is fully expressed also in other pathogenic species of *Candida*³¹.

It is known that *C. albicans* colonization of mucosal surfaces, in particular the GI tract, and skin of most healthy subjects induces strong humoral and cellular responses³². The antibody levels against the β 1,6-glucan moiety of the glucan/MP65 complex in non-candidemic, but likely *Candida*-colonized subjects, were in the same range of those previously reported in normal healthy subjects²⁹. Hence, the elevated titers of these antibodies in candidemic patients (reasonably including those against MP65) are most likely due to a booster of anti-*Candida* immune response to fungus invasion, that is expected in a generally non-immunocompromised patient population. Actually, the above booster was seen in all categories of candidemic patients irrespective of their age, sex, performance, antifungal treatment and co-morbidity (with the possible exception of diabetic patients; see below) and occurred against both the polysaccharide and, particularly high, against the protein antigen.

Despite the existence of protective anti-*Candida* antibodies, amply documented in experimental studies^{33–35}, very little is known about the existence and impact of such antibodies in clinical setting. The large majority of the studies done so far have addressed the diagnostic, rather than the prognostic, role of anti-*Candida* antibodies. Here we examined whether there was any association between levels of anti- β 1,6-glucan or anti-MP65 antibodies and disease outcome in our candidemia setting. Overall, our data show a statistically significant association between survival and antibody responses against the MP65, but not against the β 1,6-glucan, antigen in the whole candidemia population, with the expected particular strength when anti-MP65 antibody titers and survival were correlated in the categories of candidemic subjects where most of the mortality is observed (older age, diabetics, septic shock patients). Notably, the anti-MP65 titers of the diabetic, non-survivors were very close to those of non-candidemic subjects, suggesting for the inability of these patients to boost a substantial anti-*Candida* response following infection.

These data do not allow to conclude that MP65 is a protective antigen in candidemia, since it could only be an indirect marker of immune response, even of non-antibody type, against MP65 itself and/or other antigens. Bloodstream infection and sepsis is expected to cause some immune dysregulation at least in those categories of candidemic subjects heavily invaded by the fungus. Disorders in T cell and pro-inflammatory cytokines have indeed been reported that could, in some subjects, interfere with the booster of antibody responses^{17, 36}. In particular, patients with *Candida* sepsis have been reported to show a suppressive immune-phenotype including T cell exhaustion and decreased expression of co-stimulatory molecules in CD4⁺ T cells³⁶. It is therefore conceivable that in some candidemic subjects the CD4⁺ T cells are unable to express their full helper potential for antibody production. Our observation that the anti-MP65 but not the anti- β 1,6-glucan antibodies had lower titers in non-survivors is in accord with the above hypothesis, being MP65 and β 1,6-glucan, respectively, a T-helper-dependent and -independent antigen. Whichever the interpretation, our data suggest that the subjects unable to mount a more intense or more specific anti-*Candida* immunity following infection could have a worse outcome.

Our study has the well-known limitations of a retrospective one, and reporting only from a single, though large, clinical center. Some categories of subjects with high proneness to candidemia and its associated mortality (e.g. diabetics) were scarcely represented among both patients and controls. In addition, the non-candidemic, control patients were not perfectly matched for some morbidities to the candidemic patients, although belonging to the same at risk categories and largely sharing the same predisposing factor. Overall, our suggestion that the capacity to boost anti-*Candida* immunity following infection might have an impact on candidemia survival, though being statistically supported, remains highly speculative and, as such, should be taken cautiously. Nonetheless, our data invite to consider further prospective and possibly multicenter studies to assess whether antibody measurements against properly selected fungal antigens could help identify candidemic subjects with differential survival potential. These studies could suggest ways of harnessing immune responses to the infectious fungi in some categories of candidemic subjects by appropriate immune-stimulation (including vaccination) in order to improve the prognosis in a clinical setting characterized by particularly high mortality.

Methods

Study population and design. We included in the study patients with culture-proven candidemia who were hospitalized during the period from January 2012 to February 2016 at the A. Gemelli Hospital of Rome, Italy, which is an academic tertiary care center with 1,400 beds and ~50,000 hospital admissions per year. Patients were identified by electronically querying the clinical microbiology laboratory database, and were included only if complete data series could be retrieved from their medical charts and from laboratory databases, including demographics (age, sex), comorbid conditions (diabetes mellitus, chronic obstructive pulmonary disease, chronic renal failure, solid organ cancer, hematologic malignancy, human immunodeficiency virus [HIV] infection), insertion of a central venous or urinary catheter, use of immunosuppressive agents, surgery, exposure to antibiotics within 30 days of the onset of candidemia, risk days (i.e., number of hospital days from admission to the date of the first positive blood culture, antifungal therapy, and hospital mortality [the last defined as death within 30 days of the first documented candidemia episode]). The local institutional review committee approved the study, and informed consent was waived because of the observational, retrospective nature of the investigation. All patient samples and data records were rendered anonymous before performing any experimental or statistical analyses.

Diagnosis of candidemia was made on the basis of ≥ 1 blood cultures growing *Candida* species and on the presence of signs and symptoms of infection. Only the first episode of candidemia was reported for patients with recurrent or subsequent episodes of infection. In addition, only patients with β 1,3-glucanemia assay results (see below) were included.

Controls were age- and sex-matched patients who were admitted to the hospital within the same time interval as the candidemic ones, and were considered at risk for candidemia but with *Candida*-negative blood-culture and negative β -glucanemia. Only candidemic and non-candidemic patients whose serum was available in suitable quantity and quality for performing immunoassays were considered.

Microbiological assays. Blood cultures were obtained as part of normal clinical practice and processed using a Bactec (BD Diagnostic Systems, Sparks, MD) or BacT/Alert (bioMérieux, Marcy l'Etoile, France) system. After sub-culturing on Difco *Candida* bromocresol green (BCG) agar medium, yeast isolates were identified to the species level by matrix-assisted laser desorption ionization–time of flight (MALDI-TOF) mass spectrometry³⁷. Sera from blood specimens of candidemic and non-candidemic controls, as described in the previous section, were tested for β 1,3-D-glucan (BDG; Fungitell; Associates of Cape Cod Inc., Falmouth, MA) as previously described³⁸. The concentration of BDG in each sample was automatically measured within a range from 31.25 to 500 pg/ml. Using the BDG cutoffs proposed by the manufacturer, we considered a BDG to be positive if the value was ≥ 80 pg/ml and negative if the value was < 80 pg/ml.

Immunological assays. Laminarin (essentially a beta-1,3-linked glucan with occasional beta-1,6-linked side chains of a single glucose residue) and pustulan (a linear, beta-1,6-linked glucan) were used as model antigens representing β 1,3- and β 1,6- *Candida* glucans, respectively²⁹. They were purchased from Sigma Chem. Co. (St. Louis, MO) and Calbiochem (La Jolla, CA), respectively. Full length, poly-histidine tagged, recombinant MP65 protein was produced in *E.coli* by GenScript (Piscataway, NJ) and purified to homogeneity by nickel-affinity chromatography.

Sera of candidemic patients and non-candidemic controls, were extracted from the serum bank of the A. Gemelli Hospital microbiology laboratory. A single serum sample was analyzed for each subject under study. For candidemic patients, serum samples were those corresponding to laboratory diagnosis of the first candidemia episode (i.e., obtained from the same blood specimen of the first *Candida*-positive blood culture and found positive for presence of circulating β 1,3-glucan). All sera were heated at 56 °C for 30 min and stored individually at –80 °C.

Immunoglobulin G (IgG) titers against the β -glucans and MP65 antigens were determined by ELISA, essentially as already described²⁹. Briefly, polystyrene microtiter plates (MaxiSorp; NUNC, Roskilde, Denmark) coated with the antigens (50 μ g/ml polysaccharide or 0.5 μ g/ml MP65 in 0.05 M carbonate buffer, pH 9.6, 100 μ l/well, overnight at +4 °C) and blocked 2 h at 37 °C with Blocker™ Casein in PBS (Thermo Scientific, Rockford, IL, USA), were reacted with twofold dilutions of the human sera in blocking solution, followed by alkaline phosphatase-conjugated, gamma chain-specific, goat anti-human IgG (Sigma). Plates were developed 30 min with p-nitrophenyl phosphate disodium (Sigma) as the enzyme substrate and read for absorbance at 405 nm. Readings from negative control wells (wells without antigen) were subtracted from all absorbance values. Antibody titers were defined as the reciprocal of the highest dilution of sera that gave an optical density at least twice that of the correspondent negative control.

For western blot analyses, the MP65 protein preparation (2.5 μ g/lane) was separated by SDS-PAGE in 5 to 15% polyacrylamide slab gels (Bio-Rad, Hercules, CA) and transferred onto nitrocellulose (0.2-mm pore size), as previously described²⁷. After blocking of the nitrocellulose sheets for 2 h at room temperature with Blocker™ Casein in PBS (Thermo Scientific), the transferred protein was reacted for 1 h at 37 °C with control or patient sera (diluted 1:200 in Blocker™ Casein in PBS) or with a murine, anti-MP65 monoclonal IgG (7H6²⁷, 5 μ g/ml in the same diluent of human sera). Sheets were extensively washed with PBS and incubated with alkaline phosphatase-conjugated, anti-human or anti-mouse IgG antibodies, as appropriate. Reactive bands were developed with the nitroblue tetrazolium chloride/5-bromo-4-chloro-3-indolyl phosphate reagent (Sigma).

Statistics. Categorical variables were compared using the Fisher's exact test or the Chi-square test. Comparison of continuous data among groups were performed with the Mann-Whitney *U*-test, confirmed by the Student's *t* test, whereas one-way ANOVA or Kruskal-Wallis test followed by Bonferroni's or Dunn's post-tests, respectively, were used for multiple comparisons. Receiver-operator characteristics (ROC) curves were constructed to evaluate the potential of analyzed antibodies for an accurate discrimination between candidemic and non-candidemic patients. Spearman's rank correlation coefficient was calculated to assess the relationships between the different variables in patients. A *p* value < 0.05 was accepted as statistically significant. All tests were performed with the GraphPad Prism software, version 4.00 (GraphPad, San Diego CA). Relationship between survival and logarithm to base 10 of anti-MP65 and anti- β 1,6-glucan antibody titers in all candidemic patients and in patient subgroups was assessed by logistic regression analyses by the SPSS v19 software.

References

1. Wisplinghoff, H. *et al.* Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. *Clin. Infect. Dis.* **39**, 309–317, doi:10.1086/421946 (2004).
2. Falcone, M. *et al.* Identification and management of invasive mycoses in internal medicine: a road-map for physicians. *Intern. Emerg. Med.* **9**, 501–511, doi:10.1007/s11739-014-1077-4 (2014).
3. McCarty, T. P. & Pappas, P. G. Invasive Candidiasis. *Infect. Dis. Clin. North Am.* **30**, 103–124, doi:10.1016/j.idc.2015.10.013 (2016).
4. Yapar, N. Epidemiology and risk factors for invasive candidiasis. *Ther. Clin. Risk Manag.* **10**, 95–105, doi:10.2147/TCRM.S40160 (2014).
5. Tedeschi, S. *et al.* Epidemiology and outcome of candidemia in internal medicine wards: A regional study in Italy. *Eur. J. Intern. Med.* **34**, 39–44, doi:10.1016/j.ejim.2016.08.020 (2016).
6. Tortorano, A. M. *et al.* A 1-year prospective survey of candidemia in Italy and changing epidemiology over one decade. *Infection* **41**, 655–662, doi:10.1007/s15010-013-0455-6 (2013).

7. Colombo, A. L. *et al.* Prognostic factors and historical trends in the epidemiology of candidemia in critically ill patients: an analysis of five multicenter studies sequentially conducted over a 9-year period. *Intensive Care Med* **40**, 1489–1498, doi:10.1007/s00134-014-3400-y (2014).
8. Luzzati, R. *et al.* Nosocomial candidemia in patients admitted to medicine wards compared to other wards: a multicentre study. *Infection* **44**, 747–755, doi:10.1007/s15010-016-0924-9 (2016).
9. ECDC, European Centre for Disease Prevention and Control, Stockholm. Point prevalence survey of health care associated infections and antimicrobial use in European acute care hospitals. <http://ecdc.europa.eu/en/publications/publications/healthcare-associated-infections-antimicrobial-use-pps.pdf> (2013).
10. Pappas, P. G. *et al.* Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. *Clin. Infect. Dis.* **62**, e1–50, doi:10.1093/cid/civ933 (2016).
11. Pfaller, M. *et al.* Epidemiology and outcomes of candidemia in 3648 patients: data from the Prospective Antifungal Therapy (PATH Alliance(R)) registry, 2004–2008. *Diagn. Microbiol. Infect. Dis.* **74**, 323–331, doi:10.1016/j.diagmicrobio.2012.10.003 (2012).
12. Pfaller, M. A. *et al.* Epidemiology and outcomes of invasive candidiasis due to non-albicans species of *Candida* in 2,496 patients: data from the Prospective Antifungal Therapy (PATH) registry 2004–2008. *PLoS One* **9**, e101510, doi:10.1371/journal.pone.0101510 (2014).
13. Eliakim-Raz, N. *et al.* Epidemiology, microbiology, clinical characteristics, and outcomes of candidemia in internal medicine wards—a retrospective study. *Int. J. Infect. Dis.* **52**, 49–54, doi:10.1016/j.ijid.2016.09.018 (2016).
14. Bassetti, M. *et al.* Incidence, risk factors, and predictors of outcome of candidemia. Survey in 2 Italian university hospitals. *Diagn. Microbiol. Infect. Dis.* **58**, 325–331, doi:10.1016/j.diagmicrobio.2007.01.005 (2007).
15. Bassetti, M. *et al.* A multicenter study of septic shock due to candidemia: outcomes and predictors of mortality. *Intensive Care Med* **40**, 839–845, doi:10.1007/s00134-014-3310-z (2014).
16. Garey, K. W. *et al.* Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. *Clin. Infect. Dis.* **43**, 25–31, doi:10.1086/cid.2006.43.issue-1 (2006).
17. Johnson, M. D. *et al.* Cytokine gene polymorphisms and the outcome of invasive candidiasis: a prospective cohort study. *Clin. Infect. Dis.* **54**, 502–510, doi:10.1093/cid/cir827 (2012).
18. Li, F. Q. *et al.* Diagnostic value of immunoglobulin G antibodies against *Candida* enolase and fructose-bisphosphate aldolase for candidemia. *BMC Infect. Dis.* **13**, 253, doi:10.1186/147-2334-13-253 (2013).
19. Luo, T. *et al.* Immunoproteomic Analysis of Antibody Responses to Extracellular Proteins of *Candida albicans* Revealing the Importance of Glycosylation for Antigen Recognition. *J. Proteome Res.* **15**, 2394–2406, doi:10.1021/acs.jproteome.5b01065 (2016).
20. Held, J., Kohlberger, I., Rappold, E., Busse Grawitz, A. & Hacker, G. Comparison of (1- > 3)-beta-D-glucan, mannan/anti-mannan antibodies, and Cand-Tec *Candida* antigen as serum biomarkers for candidemia. *J. Clin. Microbiol.* **51**, 1158–1164, doi:10.1128/JCM.02473-12 (2013).
21. Kondori, N., Edebo, L. & Mattsby-Baltzer, I. *Candida albicans* cell wall antigens for serological diagnosis of candidemia. *Med. Mycol.* **41**, 21–30, doi:10.1080/714043895 (2003).
22. Martinez-Jimenez, M. C. *et al.* Potential role of *Candida albicans* germ tube antibody in the diagnosis of deep-seated candidemia. *Med. Mycol.* **52**, 270–275, doi:10.1093/mmy/myt025 (2014).
23. Pitarch, A., Nombela, C. & Gil, C. Seroprotection at the *Candida albicans* protein species level unveils an accurate molecular discriminator for candidemia. *J. Proteomics* **134**, 144–162, doi:10.1016/j.jpro.2015.10.022 (2016).
24. Sendid, B. *et al.* Antibodies against glucan, chitin, and *Saccharomyces cerevisiae* mannan as new biomarkers of *Candida albicans* infection that complement tests based on *C. albicans* mannan. *Clin. Vaccine Immunol.* **15**, 1868–1877, doi:10.1128/0162-1225.2008.15.1868-1877 (2008).
25. Mikulska, M., Furfaro, E. & Viscoli, C. Non-cultural methods for the diagnosis of invasive fungal disease. *Expert Rev. Anti Infect. Ther.* **13**, 103–117, doi:10.1586/14787210.2015.979788 (2015).
26. Goodridge, H. S., Wolf, A. J. & Underhill, D. M. Beta-glucan recognition by the innate immune system. *Immunol. Rev.* **230**, 38–50, doi:10.1111/j.1600-065X.2009.00793.x (2009).
27. Gomez, M. J. *et al.* Purification and biochemical characterization of a 65-kilodalton mannoprotein (MP65), a main target of anti-*Candida* cell-mediated immune responses in humans. *Infect. Immun.* **64**, 2577–2584 (1996).
28. Sandini, S. *et al.* The MP65 gene is required for cell wall integrity, adherence to epithelial cells and biofilm formation in *Candida albicans*. *BMC Microbiol.* **11**, 106–2180-11-106. (2011).
29. Chiani, P., Bromuro, C., Cassone, A. & Torosantucci, A. Anti-beta-glucan antibodies in healthy human subjects. *Vaccine* **27**, 513–519, doi:10.1016/j.vaccine.2008.11.030 (2009).
30. Klis, F. M. & Brul, S. Adaptations of the Secretome of *Candida albicans* in Response to Host-Related Environmental Conditions. *Eukaryot. Cell.* **14**, 1165–1172, doi:10.1128/EC.00142-15 (2015).
31. Arancia, S., Sandini, S., Cassone, A. & De Bernardis, F. Use of 65kDa mannoprotein gene primers in PCR methods for the identification of five medically important *Candida* species. *Mol. Cell. Probes* **23**, 218–226, doi:10.1016/j.mcp.2009.04.003 (2009).
32. Romani, L. Innate and adaptive immunity in *Candida albicans* infections and saprophytism. *J. Leukoc. Biol.* **68**, 175–179 (2000).
33. Cassone, A., De Bernardis, F. & Torosantucci, A. An outline of the role of anti-*Candida* antibodies within the context of passive immunization and protection from candidiasis. *Curr. Mol. Med.* **5**, 377–382, doi:10.2174/1566524054022549 (2005).
34. Cutler, J. E. Defining criteria for anti-mannan antibodies to protect against candidiasis. *Curr. Mol. Med.* **5**, 383–392, doi:10.2174/1566524054022576 (2005).
35. Cabezas, J. *et al.* Potential of anti-*Candida* antibodies in immunoprophylaxis. *Immunotherapy* **2**, 171–183, doi:10.2217/imt.09.76 (2010).
36. Spec, A. *et al.* T cells from patients with *Candida* sepsis display a suppressive immunophenotype. *Crit. Care* **20**, 15 doi: 10.1186/s13054-016-1182-z (2016).
37. Posteraro, B. *et al.* Antifungal susceptibility profiles of bloodstream yeast isolates by Sensititre YeastOne over nine years at a large Italian teaching hospital. *Antimicrob. Agents Chemother.* **59**, 3944–3955, doi:10.1128/AAC.00285-15 (2015).
38. Posteraro, B. *et al.* (1,3)-beta-d-Glucan-based antifungal treatment in critically ill adults at high risk of candidaemia: an observational study. *J. Antimicrob. Chemother.* **71**, 2262–2269, doi:10.1093/jac/dkw112 (2016).

Acknowledgements

This work was partly supported by Competitive Italian Gilead Fellowship Programs 2012–14 and 015–17. We thank Dr Antonino Bella for help in statistical evaluation of survival data.

Author Contributions

A.C. conceived the study, coordinated the work and drafted the paper; A.T. designed the experiments, analyzed the results and contributed to writing the paper; C.B. and P.C. performed the experiments and analyzed the data; R.C. and M.T. selected the patients and collected and analyzed the clinical information; M.S. and B.P. provided the microbiological and clinical laboratory data. All authors reviewed the final manuscript.

Additional Information

Supplementary information accompanies this paper at doi:[10.1038/s41598-017-02977-6](https://doi.org/10.1038/s41598-017-02977-6)

Competing Interests: The authors declare that they have no competing interests.

Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2017